SCHEMBL17801468

SCHEMBL17801468

Cc1nc2c(Br)cccc2cc1N

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.52
ALDH1A1 P00352 3/20 0.39
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
AR P10275 1/20 0.36
KDM4E B2RXH2 4/20 0.36
PRNP P04156 3/20 0.36
NPSR1 Q6W5P4 2/20 0.36
LMNA P02545 2/20 0.36
HTT P42858 2/20 0.36
HPGD P15428 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
NOD2 Q9HC29 1/20 0.36
NQO2 P16083 1/20 0.35
MAPT P10636 3/20 0.34
RXFP1 Q9HBX9 1/20 0.34
NR4A2 P43354 1/20 0.34
HRH4 Q9H3N8 1/20 0.34
GAA P10253 1/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17942847 0.81 MAPT (0.44) ALDH1A1MEN1KMT2AKDM4ENPSR1
SCHEMBL7547167 0.81 BACE1 (0.46) BACE1ALDH1A1MEN1KMT2AAR
SCHEMBL28153007 0.78 KMT2A (0.60) ALDH1A1MEN1KMT2AKDM4EHPGD
SCHEMBL31716582 0.78 BACE1 (0.43) BACE1ALDH1A1MEN1KMT2AAR
SCHEMBL2717498 0.78 SMN1; SMN2 (0.41) ALDH1A1MEN1KMT2AARKDM4E
Hydrochloric Acid SCHEMBL28213132 0.76 KMT2A (0.58) ALDH1A1MEN1KMT2AKDM4EHPGD
SCHEMBL5264894 0.76 PRNP (0.62) ALDH1A1MEN1KMT2AKDM4EPRNP
SCHEMBL7983249 0.75 BACE1 (0.56) BACE1ALDH1A1ARKDM4ELMNA
SCHEMBL17942612 0.75 MCHR1 (0.57) ALDH1A1MEN1KMT2AKDM4ELMNA
SCHEMBL17801432 0.73 ALDH1A1 (0.47) BACE1ALDH1A1MEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025227032-A1 METHODS FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES REMIX THERAPEUTICS INC. (US) 2025-10-30 WO disclosed
EP-3247692-B1 INHIBITORS OF TRKA KINASE GVK BIOSCIENCES PRIVATE LTD (IN) 2022-09-07 EP disclosed
US-10336723-B2 Inhibitors of TrkA kinase GVK BIOSCIENCES PRIVATE LIMITED (IN) 2019-07-02 US disclosed
US-20180009781-A1 INHIBITORS OF TRKA KINASE GVK BIOSCIENCES PRIVATE LIMITED (IN) 2018-01-11 US disclosed
EP-3247692-A1 INHIBITORS OF TRKA KINASE GVK Biosciences Private Limited (IN) 2017-11-29 EP disclosed
WO-2016116900-A1 INHIBITORS OF TRKA KINASE GVK BIOSCIENCES PRIVATE LIMITED (IN) 2016-07-28 WO disclosed
WO-2016087593-A1 NOVEL FUNGICIDAL QUINOLINYLAMIDINES SYNGENTA PARTICIPATIONS AG (CH) 2016-06-09 WO disclosed
WO-2016087593-A1 NOVEL FUNGICIDAL QUINOLINYLAMIDINES SYNGENTA PARTICIPATIONS AG (CH) 2016-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180009781-A1 INHIBITORS OF TRKA KINASE NGFR, NGF, NTRK1 BACE1 508/4885ALDH1A1 2186/4885MEN1 2623/4885
US-10336723-B2 Inhibitors of TrkA kinase NGFR, EDNRA, NGF BACE1 381/4885ALDH1A1 2317/4885MEN1 2623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.